SLE treatment with N-acetylcysteine

Active Cooperative Agreement Awarded Last action

Award ID
U01AR076092
Recipient
Awarding agency
Obligated
$17,806,595

Award facts

Completion date 92% complete
Originally
Funding
  • $16,420,228.00 Federal
  • $1,386,367.00 Non-federal
Place of performance
Syracuse, NY 13210, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment SLE treatment with N-acetylcysteine - scientific abstract systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still… $862,700 $0
Amendment SLE treatment with N-acetylcysteine - systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still approaching 10% in… $0 $0
Amendment SLE treatment with N-acetylcysteine - scientific abstract systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still… $0 $0
Amendment $0 $0
Amendment SLE treatment with N-acetylcysteine - systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still approaching 10% in… $0 $0
Amendment SLE treatment with N-acetylcysteine - scientific abstract systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still… $0 $0
Amendment $1,310,215 $0
Amendment $1,310,215 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,437,594 $0
Amendment $1,437,594 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,447,294 $0
Amendment $1,447,294 $0
Amendment $1,447,294 $0
Amendment $1,447,294 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,386,367 $0
Amendment SLE treatment with N-acetylcysteine - systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still approaching 10% in… $1,386,367 $1,386,367
Original award $1,500,000 $0
Show all 29

Subawards

Subrecipient Amount Awarded
Emory University STUDY DESIGN All participants will receive NAC for a 3-month open-label period, titrated up to the individual’s maximally tolerated dosage between… $49,685
The Trustees Of Columbia University In The City Of New York STUDY DESIGN All participants will receive NAC for a 3-month open-label period, titrated up to the individual’s maximally tolerated dosage between… $81,689
The Hospital For Special Surgery Fund, Inc. STUDY DESIGN All participants will receive NAC for a 3-month open-label period, titrated up to the individual’s maximally tolerated dosage between… $63,163
Saint Luke's Hospital Of Bethlehem, Pennsylvania Statement of Work for SNAC Clinical Trial The work to be conducted at this site includes all aspects of a clinical trial including but not limited:… $46,852
The Ohio State University STUDY DESIGN All participants will receive NAC for a 3-month open-label period, titrated up to the individual’s maximally tolerated dosage between… $37,563

Quick answers

Who received award U01AR076092?

U01AR076092 was awarded to The Research Foundation For The State University Of New York by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on June 15, 2020.

How much is award U01AR076092 worth?

$17,806,595 has been obligated on U01AR076092: $16,420,228 in federal funding and $1,386,367 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login